natgillin/translations-raw huggingface dataset:
The procedure consists in a 1 minute period of familiarisation of the rats in the test cage, followed by the series of tests the start of which is signalled by the light stimulus; the discriminatory stimulus is followed, a few seconds later, by the administration of an electric shock. 
Postupak se sastoji u periodu od 1 minute upoznavanja štakora u testnom kavezu, nakon čega slijedi serija testova početak kojih se signalizira svjetlosnim stimulativnim poticajom; diskriminacijski poticaj slijedi, nekoliko sekundi kasnije davanjem clektričnog šoka.
Adhesive composition in form of a paste according to one or more of the previous claims 1-4, 6-8, 10-11, 14-16, having the following composition: 
Adhezivna kompozicija u obliku paste u skladu sa jednim ili više prethodnih patentnih zahtjeva 1-4, 6-8, 10-11, 14-16, koja ima sljedeći sastav: i)
testing said antibody in in-vitro assays selecting an antibody, which inhibits GCO and/or cell proliferation. 
HR P20150224 T1 b) ispitivanje spomenutog protutijela u analizama in-vitro, C) -odabiranje protutijela koje inhibira GCO i/ili staničnu proliferaciju.
mounting said support on a distal end of said at least one insulator, and 
montiranje navedenog podupirača na distalnom kraju od najmanje jednog izolatora (12),
The lyophilized preparation according to claim 8, wherein the meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide is an amorphous product. 
Liofilizirani pripravak u skladu s patentnim zahtjevom 8, naznačen time, da je megluminska sol 6-fluoro-3-hidroski-2-pirazinkarboksamida amorfan produkt.
A pharmaceutical composition comprising a therapeutically effective amount of a compound having the following Formula I: 
Farmaceutska smjesa koja sadrži terapijski učinkovitu količinu spoja prema Formuli I: Ho
After stirring at room temperature for 4 hours, the reaction mixture is filtered to remove any undissolved material and is evaporated to dryness. 
Nakon miješanja 4 sata pri sobnoj temperaturi, reakcijsku smjesu se profiltrira da se odstrani sav neotopljen materijal i ispari se do suhog.
computer code for accessing receiver specific information (S10B) according to the identifier of the receiver sent by the sender and encrypting (S11B), with the receiver specific information, said transfer specific encryption key; computer code for transferring the encrypted data and the encrypted transfer specific encryption key over the network (S12B) for receipt by the receiver; 
Kompjuterski kod za pristup specifičnim informacijama primatelja (S10B), prema identifikatoru primatelja koji je poslao pošiljatelj i enkripcija (S11B), sa specifičnim informacijama primatelja, navedenog specifičnog enkripcijskog ključa prijenosa;
to 250 g per litre PEG having an average molecular weight of 2500 to 4500 Da; 
(i) 70 do 250 g po litri PEG koji ima prosječnu molekularnu težinu od 2500 do 4500 Da;
a nucleotide sequence encoding at least one glycosyltransferase from a Gram-positive bacterium; 
nukleotidni slijed koji kodira najmanje jednu glikozil-transferazu iz Gram-pozitivne bakterije, gdje je navedena Gram-pozitivna bakterija Staphylococcus aureus;
A compound for use in the treatment of a disease caused at least in part by an organism selected from the group consisting of Bacillus anthracis, Yersinia pestis, Francisella tularensis, and Burkholderia mallei, and combinations thereof; where the compound is of the formula or a pharmaceutically acceptable salt thereof, wherein: 
PATENTNI ZAHTJEVI snom Fon Spoj za uporabu u liječenju bolesti koju uzrokuje barem djelomično organizam izabran iz grupe koju čine Bacillus anthracis, Yersinia pestis, Francisella tularensis i Burkholderia mallei, i njihove kombinacije; gdje spoj ima formulu ili njegova farmaceutski prikladna sol, gdje:
and a potentiating agent selected from the group consisting of: cyclophosphamide, an analog of cyclophosphamide, sunitinib, anti-TGFB, imatinib, anthracyclines, oxaliplatin and doxorubicin; 
i sredstvo za pojačavanje koje je odabrano iz skupine koja sadrži: ciklofosfamid, analog ciklofosfamida, sunitinib, anti-TGFB, imatinib, antracikline, oksaliplatin i doksorubicin;
wherein the synthetic retinyl ester is a 9-cis-retinyl ester having a structure as represented by Formula I or an 11-cis-retinyl ester having a structure as represented by Formula II, wherein A in each formula is CH2OR and —R, along with the adjacent oxygen, forms a retinyl ester, and the ester substituent comprises a carboxylate radical of a C1 to C10 monocarboxylic acid or a C2 to C22 polycarboxylic acid: 
Upotreba derivata 9-cis-retinala čija je struktura predstavljena Formulom I, [image] pri čemu A predstavlja CH2OR, a R tvori retinil ester, naznačena time, da je to upotreba za pripravu lijeka za liječenje endogene deficijencije 11-cis- retinala kod ljudskog subjekta. Upotreba iz patentnog zahtjeva 17, naznačena time, da je derivat retinala 9-cis-retinil ester, pri čemu esterski supstituent sadržava karboksilatni radikal C1-C10 monokarboksilne kiseline ili C2-C22 polikarboksilne kiseline.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. 
Prikladna zaštitna skupina za karboksi skupinu je, na primjer, esterificirajuća skupina, na primjer metil ili etil skupina koja može biti uklonjena, na primjer, hidrolizom pomoću baze poput natrij hidroksida, ili na primjer t-butil skupina koja može biti uklonjena, na primjer, u reakciji sa kiselinom, primjerice organskom kiselinom poput trifluorooctene kiseline, ili na primjer benzil skupina koja može biti uklonjena, na primjer, hidrogenacijom na katalizatoru poput paladija-na-ugljiku.
A pharmaceutical composition comprising the antibody according to claims 1 to 3 or 8 and a pharmaceutically acceptable carrier. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 3 or 8 for use in a method of treating cancer. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 4 ili 12 do 17, ili koje se proizvodi putem postupka prema zahtjevu 11, te farmaceutski prihvatljiv nosač.
a peptide consisting of the amino acid sequence of SEQ ID NO: 32 when presented on an MHC molecule. A pharmaceutical composition comprising a T-cell mixture according to claim 1, and a pharmaceutically-acceptable carrier, diluent and/or excipient. 
Farmaceutska kompozicija koja sadrži peptidnu smjesu iz bilo kojeg od patentnih zahtjeva 1-3, ili smjesu T stanica iz patentnog zahtjeva 4 i farmaceutski prihvatljiv nosač, razblaživač i/ili ekscipijens.
two ring shaped flat surfaces (71, 72) of thermally insulating material are attached around the exterior of the ring shaped section layer (70), 
- > sa vanjske strane spomenutog pojasa termoizolacijskog materijala (70) postavljene su dvije prstenaste ravne površine (71, 72) koje su također izvedene od termoizolacijskog materijala;
identifying the modified mouse ES cell comprising the targeted genetic modification at the genomic locus of interest; 
(b) identifikaciju modificirane mišje ES stanice koja sadrži ciljnu genetičku modifikaciju na genomskom lokusu od interesa;
The first segment, comprising a nucleotide sequence that is complementary to a target sequence in a target DNA, is referred to herein as a “targeting segment”. 
(i) segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
The antibody of any one of claims 1-5, wherein CLDN6 has the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 8. 
Protutijelo sukladno bilo kojem od patentnih zahtjeva 1-7, pri čemu navedeni izvanstanični dio CLDN6 obuhvaća sekvencu amino kiseline iz SEK ID BR: 6 ili SEK ID BR: 7.
A pharmaceutical composition comprising a crosslinked cation exchange polymer salt and from 10 wt.% to 40 wt.% of a linear sugar based on the total weight of the composition, the crosslinked cation exchange polymer comprising structural units corresponding to Formulae 1 and 2, Formulae 1 and 3, or Formulae 1, 2, and 3, wherein Formula 1, Formula 2, and Formula 3 are represented by the following structures: wherein 
Oralni oblik doziranja koji sadrži pripravak i jednu ili više pomoćnih tvari, pri čemu pripravak sadrži 15 mas. % do 35 mas. % ravnolančanog šećernog alkohola, 10 mas. % do 25 mas. % vode i ostatak je umreženi polimer za kationsku izmjenu, gdje su maseni postotci u odnosu na ukupnu masu ravnolančanog šećernog alkohola, vode i polimera, pri čemu umreženi polimer za kationsku izmjenu obuhvaća strukturne jedinice koje odgovaraju Formulama 1, 2, i 3, naznačen time što
The most straightforward preparative method is that initiated by radicals. 
Najizravnija preparativna metoda je ta započeta radikalima.
A pharmaceutical composition in the form of hydrophilic gel for transvaginal administration comprising a phosphodiesterase inhibitor, a polyhydroxy alcohol, water, a carbomer and an alkaline agent, wherein the phosphodiesterase inhibitor is selected from the group consisting of pentoxifylline, rolipram, milrinone and ibudilast. 
Farmaceutski pripravak u obliku hidrofilnog gela za transvaginalnu primjenu sadrži inhibitor fosfodiesteraze, polihidroksilni alkohol, vodu, karbomer 1 alkalni agens, pri čemu je inhibitor fosfodiesteraze odabran iz skupine koja se sastoji od pentoksifillina, roliprama, milrinona i ibudilasta.
A suitable application rate is typically in the range from about 0.10 to about 4 pounds/acre (about 0.01 to 0.45 grams per square meter, g/m2). 
Postupak prema patentnom zahtjevu 4, naznačen time, da fungicidno učinkovita količina jest od 0,01 do 0,45 grama po kvadratnom metru.
Therefore co-biocides are introduced to copper-ethanolamine based aqueous solution to increase protection against copper tolerant fungi. 
Prema tome, uvode se ko-biocidi u vodenu otopinu na bazi bakar-etanolamina, da bi povećali zaštitu od gljivica otpornih na bakar.
Milling of the Drug Resin Complex until particle size gets less than 250µm; 
Mljevenje kompleksa lijeka 1 smole dok veličina čestica ne postane manja od 250um;
the magnesium stearate is present in an amount from 0.1% to 3% by weight. 
(d) magnezij stearat je prisutan količinom od 0.1% do 3% mase.
The process of the invention includes: 
Datum objave europske prijave patenta:
Optionally, the coating composition may also include any or all of from about 0.05% to about 1% antimicrobrials, preferably methylparaben; a small amount of plasticizer, e.g., polysorbate from about 0.01% to 10% by weight of polyvinylidene chloride copolymer; and, preferably about 0.005% of an antifoaming agent, such as polydimethylsiloxane. 
Izborno, oblagajuća kompozicija također može sadržavati bilo koji ili sve od: od oko 0.05% do oko 1% antimikrobnih sredstava, poželjno metilparaben, malu količinu plastifikatora, npr. polisorbat od 0.01% do 10% po masi poliviniliden klorid kopolimera; i, poželjno 0.005% sredstva protiv stvaranja pjene, kao što je polidimetil-siloksan.
is selected from t-butyl, methyl, isopropyl, phenyl and hydroxyl. 
R4 je odabran od t-butila, metila, izopropila i fenila.
These two are glued together. 
Ova dva su zajedno zalijepljena.
A strain of Wistar rats with spontaneously generalized non convulsive seizures (absence seizures) has been developed in Strasbourg (Genetic Absence Epilepsy Rats of Strasbourg or GAERS). 
Soj štakora Wistar sa spontanim općim nekonvulzivnim napadima (apsans) dobiven je u Strasburgu (Genetic Absence Epilepsy Rats of Strasbourg ili GAERS).
The clear solution obtained in this way is sterilized by filtration and can then be dispensed into ampoules or containers for eye drops or containers for nasal administration. 
Na ovaj način dobivena bistra otopina se sterilizira filtrirajem 1 može se distribuirati u ampulama ili spremnicima za očne kapi ili spremnicima za nazalnu primjenu.
According to this method, the 3-ketoester of formula (IV), wherein R1 and R3 are as defined for compound of formula (I) and R is an alkyl group such as for example methyl or ethyl, is allowed to react with a compound of formula (V). 
HR P20070328 T3 Ovim postupkom 3-ketoester formule (IV), gdje R1 i R3 su definirani kao za spoj formule (1), a R je alkilna skupina, poput primjerice metila ili etila, može reagirati sa spojem formule (V).
Products for use according to claim 25 wherein the at least one antibody or functional fragment thereof which inhibits osteoclast formation and/or osteoclastic bone resorption is a monoclonal antibody or functional fragment thereof in accordance with any one of claims 1 to 15. 
Preparati za uporabu prema zahtjevu 25, pri čemu je najmanje jedno antitijelo ili njegov funkcionalni fragment, koji inhibiraju razvoj osteoklasta i/ili osteoklastnu resorpciju kostiju, monoklonsko antitijelo ili njegov funkcionalni fragment sukladno bilo kojem od zahtjeva 1-15.
The reaction mixture is cooled and concentrated under reduced pressure. 
Reakcijsku smjesu se ohladi, te koncentrira pod sniženim tlakom.
Evacuating means can be arranged for selectively connecting the inlet side of the steam-producing thermoblock with the evacuation outlet. 
Mehanizam za pražnjenje može se podesiti za selektivno povezivanje izlazne strane termobloka za dobivanje vodene pare s izlazom za pražnjenje.
The composition of any one of claims 1 to 9, wherein said composition is for administration every 12 hours. 
Sastav prema bilo kojem od zahtjeva 1 do 9, naznačen time da spomenuti sastav osigurava srednju vrijednost Tax od oko 1 do oko 6 sati ili od oko 2 do oko 5,2 sata nakon primjene.
The method of claim 1, wherein the coding method uses 5-bit fixed representation for the remaining mode set. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time što postupak kodiranja upotrebljava 5-bitnu fiksnu reprezentaciju za skup preostalih modova.
Vegetable fat blend according to claim 1 or 2, wherein the vegetable fat blend is characterised by the following solid fat profile: 20% ≤ N10 ≤ 45%; 
Smjesa biljnih masti u skladu s patentnim zahtjevom 1 ili 2, naznačena time što navedena smjesa biljnih masti ima sljedeći profil čvrstih masti:
The composition of claim 1, wherein the first constituent is chemically modified through an amidation with the monomer PA or PRE-PA or a combination of both. 
Sastav prema zahtjevu 1 ili 5, u kojem je prvi sastojak kemijski modificiran kroz amidaciju s monomerom PA 1li PRE-PA ili kombinacijom oba.
Examples of such conditions include the use of phosphorus-based dehydrating agents such as phosphorus halides or phosphorus oxyhalides, e.g. POCl3 and PCl5. 
Primjeri takvih stanja uključuju uporabu sredstava za dehidriranje na bazi fosfora poput fosfor halida ili fosfor oksihalida, na primjer POCl; i PCls.
Subject of the present invention is further an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of acute disease of a patient according to the present invention, wherein said antibody or antibody fragment or non-Ig scaffold is to be used in combination of ADM binding protein. 
Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 3, pri čemu je spomenuto antitijelo ili fragment antitijela ili non-Ig skela monospecifično.
A camouflage device (10) according to claim 1, further comprising at least one coating layer (14) affixed to said substrate, wherein said visible pattern is part of said coating layer. 
Naprava za prikrivanje (10) iz zahtjeva 1, koja se još sastoji od najmanje jedne obloge (14) pričvršćene za goru navedenu podlogu, pri čemu gore navedeni uzorak predstavlja dio obloge.
the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 127 or a fragment thereof, 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 134 i varijabilno područje lakog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 140;
The monoamine reuptake inhibitors which may be optionally employed in combination with compound of the present invention include fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine, paroxetine, sertraline, chlorphentermine, cloforex, clortermine, picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamine or mazindol. 
Inhibitori ponovnog preuzimanja monoamina koji se mogu izborno koristiti u kombinaciji sa spojem prema ovom izumu obuhvaćaju fenfluramin, deksfenfluramin, fluvoksamin, fluoksetin, paroksetin, sertralin, klorfentermin, kloforeks, klortermin, piciloreks, sibutramin, deksamfetamin, fentermin, fenilpropanolamin ili mazindol.
The rim block cage according to one of the preceding claims, characterized in that spacers (14a, 14b) which space the preparation (4a, 4b, 4c, 4d) apart from the outlet opening (6a, 6b, 6c, 6d) are formed in at least one, preferably in all containers (3a, 3b, 3c, 3d). 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su elementi za održavanje razmaka (14a, 14b) oblikovani u barem jednom, poželjno u svim spremnicima (3a, 3b, 3c, 3d), koji razmiču pripravke (4a, 4b, 4c, 4d) dalje od izlaznih otvora (6a, 6b, 6c, 6d).
The phrase DISORDERS OF LIPID METABOLISM is intended herein to include, but not be limited to, dyslipidemia. 
Fraza POREMEĆAJ METABOLIZMA LIPIDA namjerava obuhvatiti, ali se ne ograničava na, dislipidemiju.
Machining tool according to claim 5, characterized in that the cutters (2, 2 ′) embodied as circumference cutters are arranged in pairs with opposite orientation. 
Alat za obradu prema zahtjevu 5, naznačen time da su noževi (2, 2') postavljeni u parove koji rade u suprotnim smjerovima,
wherein the pharmaceutical composition maintains at least 90% of the amount of ketorolac or a pharmaceutically acceptable salt thereof after storage for 6 months at 25° C. A method of preparing a pharmaceutical composition for parenteral administration comprising: preparing an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL and a pharmaceutically acceptable excipient selected from the a group consisting of trehalose, anhydrous or hydrous forms of sodium chloride, dextrose, sucrose, xylitol, fructose, glycerol, sorbitol, mannitol, potassium chloride, mannose, calcium chloride, and magnesium chloride, 
Farmaceutski pripravak za parenteralnu primjenu koja sadrži: vodena otopina koji sadrži ketorolak ili njegovu farmaceutski prihvatljivu sol u količini od 0.1 mg/mL do 10 mg/mL; i farmaceutski prihvatljivi ekscipijent odabran iz skupine sastavljen od trehaloze, bezvodnog ili hidratnog oblika natrij klorida, dekstroze, saharoze, ksilitola, fruktoze, glicerola, sorbitola, kalij klorida, manoze, kalcij klorida i magnezij klorida; pri čemu pripravak ne sadrži alkohol; i pri čemu pripravak zadržava najmanje 90% količine ketorolaka ili njegove farmaceutski prihvatljive soli nakon skladištenja 6 mjeseci.
In Figure 1,1 denotes a sampler according to the invention. 
Na slici 1 je brojem 1 označena naprava za uzimanje uzorka, koja naprava je u skladu s ovim izumom.
the heavy chain complementary determining region 1 (HCDR1) includes the amino acid sequence of SEQ ID NO: 2323, the HCDR2 includes the amino acid sequence of SEQ ID NO: 2324 and the HCDR3 includes the amino acid sequence of SEQ ID NO: 2325; the light chain complementarity determining region 1 (LCDR1) includes the amino acid sequence of SEQ ID NO: 2326, the LCDR2 includes the amino acid sequence of SEQ ID NO: 2327 and the LCDR3 includes the amino acid sequence of SEQ ID NO: 2328; and 
HCDR1 regije za određivanje komplementarnosti teškog lanca koji sadrži aminokiselinsku sekvencu od SEK ID BR: 2323, HCDR2 sadrži aminokiselinsku sekvencu od SEK ID BR: 2324 i HCDR3 sadrži aminokiselinsku sekvencu od SEK ID BR: 2325 i LCDR1 regije za određivanje komplementarnosti lakog lanca sadrži aminokiselinsku sekvencu od SEK ID BR: 2326, LCDR2 sadrži aminokiselinsku sekvencu od SEK ID BR: 2327 i LCDR3 sadrži aminokiselinsku sekvencu od SEK ID BR: 2328; i
is hydrogen, alkyl, alkenyl, alkynyl, or halogen, wherein said alkyl is unsubstituted or substituted with one or more Rc; 
R* je alkil, alkenil, alkinil ili halogen, pri čemu je navedeni alkil nesupstituiran ili supstituiran s jednim ili više R;
The formulation of claim 3, wherein the further coating comprises ethylcellulose or ethyl acrylate methyl methacrylate copolymer. 
smjese pH-ovisnih polimera i u vodi netopljivih, pH-neovisnih polimera kao što je etilceluloza ili kopolimer etil akrilat metil metakrilata (NE30D).
a sense strand complementary to an antisense strand, wherein said antisense strand comprises a region complementary to part of an mRNA encoding PCSK9, wherein each strand is about 17 to about 30 nucleotides in length, wherein said antisense strand comprises at least 17 nucleotides from the nucleobase sequence ACAAAAGCAAAACAGGUCUAG (SEQ ID NO: 412) and the double stranded RNAi agent is represented by formula (III): wherein: 
(a) sense lanac komplementaran sa antisense lancem, pri čemu navedeni antisense lanac sadrži regiju komplementarnu s dijelom mRNA koja kodira PCSKO, pri čemu je svaki lanac duljine oko 17 do oko 30 nukleotida, pri čemu navedeni antisense lanac sadrži barem 17 nukleotida iz sekvence nukleobaze ACAAAAGCAAAACAGGUCUAG (SEQ ID NO: 412) i dvolančano RNAi sredstvo je predstavljeno s formulom (III): sense:
a second soluble TNF family cytokine domain, 
(iii) drugu topljivu citokinsku domenu iz TNF obitelji,
within the 24 hours preceding administration of said medicament), intermediate (e.g. 
unutar 24 sata koji su prethodili davanju navedenog medikamenta), prijelazno (na pr.
The compound or salt of claim 54 wherein said skin disorder is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization. 
Spoj ili sol prema zahtjevu 54 naznačen time da navedeni kožni poremećaj je atopijski dermatitis, psorijaza, osjetljivost kože, iritacija kože, kožni osip, kontaktni dermatitis ili alergijska kontaktna osjetljivost.
The method of claim 1, wherein the variant TIR comprises sequence of one of SEQ ID NOs. 1-14, 16-24, 26-39, 41-42. A method of making an antibody, said method comprising culturing a host cell comprising a polynucleotide comprising (1) a first TIR operably linked to a polynucleotide encoding an antibody heavy chain, wherein the TIR comprises a co-translational prokaryotic secretion signal sequence; and (2) a second TIR operably linked to a polynucleotide encoding an antibody light chain, wherein the second TIR comprises a co-translational or post-translational prokaryotic secretion signal sequence, so that the antibody is expressed, whereby upon expression of the antibody in the host cell, the heavy and light chains are folded and assembled to form a biologically active antibody, 
Postupak priprave protutijela, naznačen time, da spomenuti postupak obuhvaća kultiviranje stanice domaćina koja sadrži polinukleotid s (1) prvim područjem inicijacije translacije (TIR) koje je funkcionalno povezano s polinukleotidom koji kodira protutijelo jakog lanca, pri čemu TIR obuhvaća signalnu sekvencu DsbA prokariotske kotranslacijske sekrecije, odabranu iz skupine koja se sastoji od SEQ ID NO:36 do SEQ ID NO:39, SEQ ID NO:41 i SEQ ID NO:42; te s (2) drugim TIR-područjem koje je funkcionalno povezano s polinukleotidom koji kodira protutijelo slabog lanca, dok drugo TIR-područje obuhvaća signalnu sekvencu prokariotske kotranslacijske ili posttranslacijske sekrecije, pri čemu se nakon ekspresije protutijela u stanici domaćina, jaki i slabi lanci preklapaju i sklapaju u svrhu tvorbe biološki djelotvornog protutijela.